Pharmacological subgroup
B01A – ANTITHROMBOTISCHE MITTEL
8Decisions
14Patient groups
Added benefit by patient group
- Considerable1
- Minor5
- Non-quantifiable2
- Not proven6
Subgroups
- B01AC Thrombozytenaggregationshemmer, exkl. Heparin 2 decisions
- B01AF Direkte Faktor-Xa-Inhibitoren 4 decisions
- B01AX Andere antithrombotische Mittel 2 decisions
Decisions, newest first
- 2021-01-07CabliviCaplacizumabNon-quantifiable
- 2019-03-22CabliviCaplacizumabNon-quantifiable
- 2016-09-15BriliqueTicagrelorMinor
- 2016-01-21LixianaEdoxabanMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2015-02-19EliquisApixabanMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2013-06-20EliquisApixabanMinor
- 2012-06-07EliquisApixabanMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2011-12-15BriliqueTicagrelorConsiderable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
Data status: 2026-10-29